IL-17 has the double effect of promoting or preventing atherosclerotic plaques Taleb et al. (2015). IL-17 therapy didn’t demonstrate an increased risk of cardiovascular diseases in a few short-term studies Wu et al. (2017b), Rungapiromnan et al. (2017), Armstrong et al. (2020). More long-term prospective studies are ongoing. Here, IL17A is linked to cardiovascular disorder.